Camptothecin: therapeutic potential and biotechnology

Area of Science:

• Pharmacology
• Plant Sciences
• Biotechnology

Background:

• Camptothecin (CPT) and its derivatives are significant anticancer agents, with topotecan and irinotecan already in clinical use.
• Currently, CPT is primarily sourced through extraction from plant species like Camptotheca acuminata and Nothapodytes foetida.
• The demand for CPT necessitates exploring alternative and sustainable production methods beyond traditional plant extraction.

Purpose of the Study:

• To investigate alternative sources and methods for sustainable Camptothecin (CPT) production.
• To explore the potential of microbial and plant cell culture systems for CPT synthesis.
• To identify novel avenues for the large-scale production of CPT and its derivatives.

Main Methods:

• Review of existing literature on Camptothecin (CPT) production from various natural sources.
• Analysis of studies on in vitro cell cultures, including hairy root cultures of CPT-producing plants.
• Examination of reports on CPT production by endophytic fungi associated with CPT-producing plants.

Main Results:

• Camptothecin (CPT) has been identified as a product of endophytic fungi isolated from Nothapodytes foetida.
• Hairy root cultures of Camptotheca acuminata and Ophiorrhiza pumila demonstrate high-yield CPT production and secretion into the medium.
• Advances in understanding the CPT biosynthetic pathway enzymes offer potential for genetic engineering approaches.

Conclusions:

• Microbial and advanced plant cell culture techniques present viable alternatives for sustainable, large-scale Camptothecin (CPT) production.
• The discovery of fungal CPT production broadens the scope of natural sources for this anticancer compound.
• Future research directions include metabolic engineering and synthetic biology for enhanced CPT yields.